Early-stage biotech Naked Biome is a micro biome based skin therapeutics startup with a Phase IB acne study using a topical live biologic, indicating a progressive clinical path and potential for early partnerships in dermatology-focused drug discovery and clinical development services.

Private funding With about $17M in funding and revenue under $1M, the company shows a startup-like creation phase, suggesting opportunities for strategic investors and potential collaborators to support scale-up, manufacturing collaborations, and co-development deals.

Dermatology focus Core emphasis on skin health and microbiome therapeutics positions Naked Biome for partnerships with dermatology clinics, contract research organizations, and consumer health players seeking advanced microbiome-based solutions for acne and related skin conditions.

Tech-enabled discovery A proprietary genomics platform for drug discovery in skin diseases, combined with a modern tech stack, implies potential collaboration on data analytics, biomarker development, and scalable computational biology services for larger pharma or biotech partners.

Competitive positioning Comparative context with niche players and notable firms in the wellness and biotech space suggests opportunities to pursue business development in joint ventures, licensing, or exclusive rights for pipeline expansion, leveraging their Phase IB acne program to demonstrate proof of mechanism and safety.